A pharmaco-EEG study of the interaction between ethanol and retigabine in rabbits

References

• Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149–154
   PubMed Web of Science ®Google Scholar
• Splinter MY. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis 2013;5:31–41
   PubMedGoogle Scholar
• Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591–600
   PubMed Web of Science ®Google Scholar
• Kapetanovic IM, Yonekawa WD, Kupferberg HJ. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res 1995;22:167–173
   PubMed Web of Science ®Google Scholar
• Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interactions with GABAergic and glutamergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50:1063–1070
   PubMed Web of Science ®Google Scholar
• Sills GJ, Rundfeldt C, Butler E, Forrest G, Thompson GG, Brodie MJ. A neurochemical study of the novel antiepileptic drug retigabine in mouse brain. Pharmacol Res 2000;42:553–557
   Google Scholar
• Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012;53:412–424
   PubMed Web of Science ®Google Scholar
• Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 2006;51:283–294
   PubMed Web of Science ®Google Scholar
• Mora G, Tapia R. Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in the rat hippocampus in vivo. Neurochem Res 2005;30:1557–1565
   Google Scholar
• Seyfried J, Evert BO, Rundfeldt C, Schulz JB, Kovar KA, Klockgether T, Wüllner U. Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. Eur J Pharmacol 2000;400:155–166
   Google Scholar
• Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109–116
   PubMed Web of Science ®Google Scholar
• Richter A, Sander SE, Rundfeldt C. Antidystonic effects of Kv7 (KCNQ) channel openers in the dtsz mutant, an animal model of primary paroxysmal dystonia. Br J Pharmacol 2006;149:747–753
   PubMedGoogle Scholar
• Sander SE, Lemm C, Lange N, Hamann H, Richter R. Retigabine, a Kv7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats. Neuropharmacology 2012;62:1052–1061
   Google Scholar
• Dencker D, Dias R, Pedersen ML, Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav 2008;12:49–53
   PubMed Web of Science ®Google Scholar
• Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res 2010;207:78–83
   PubMedGoogle Scholar
• Korsgaard MPG, Hartz BP, Brown WD, Ahring PK, Strøbæk D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 2005;314:282–292
   PubMedGoogle Scholar
• Hansan HH, Andreasen JT, Weikop P, Mirza N, Scheel-Krüger J, Mikkelsen JD. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 2007;570:77–88
   Google Scholar
• Knapp CM, O’Malley M, Datta S, Ciraulo DA. The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats. Am J Drug Alcohol Abuse 2014;40:244–250
   PubMed Web of Science ®Google Scholar
• Pietrzak B, Czarnecka E. The effect of combined administration of ethanol and gabapentin on rabbit electroencephalographic activity. Basic Clin Pharmacol Toxicol 2006;99:383–390
   Google Scholar
• Pietrzak B, Czarnecka E. Pharmaco-EEG-based assessment of interaction between ethanol and levetiracetam. Alcohol 2008;42:115–122
   Google Scholar
• Pietrzak B, Czarnecka E. Pharmaco-EEG-based assessment of interaction between ethanol and oxcarbazepine. Pharmacol Rep 2010;62:278–286
   Google Scholar
• Sawyer CH, Everett JW, Green JD. The rabbit diencephalon in stereotaxic coordinates. J Comp Neurol 1954;101:801–824
   PubMed Web of Science ®Google Scholar
• Tinel N, Lauritzen I, Chouabe C, Lazdunski M, Borsotto M. The KCNQ2 potassium channel: splice variants, functional and developmental expression. Brain localization and comparison with KCNQ3. FEBS Lett 1998;438:171–176
   PubMed Web of Science ®Google Scholar
• Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 2000;275:24089–24095
   PubMed Web of Science ®Google Scholar
• Cavaliere S, Gillespie JM, Hodge JJ. KCNQ channels show conserved ethanol block and function in ethanol behaviour. PLoS 2012;7:e50279
   Google Scholar
• Koyama S, Appel SB. Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 2006;96:535–543
   Google Scholar
• Sotty F, Damgaard T, Montezinho LP, Mørk A, Olsen CK, Bundgaard C, Husum H. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther 2009;328:951–962
   PubMedGoogle Scholar
• Brodie MS, Appel SB. Dopaminergic neurons in the ventral tegmental area of C57BL/6J and DBA/2J mice differ in sensitivity to ethanol excitation. Alcohol Clin Exp Res 2000;24:1120–1124
   PubMed Web of Science ®Google Scholar
• Roberto M, Gilpin NW, Siggins GR. The central amygdala and alcohol: role of γ-aminobutyric acid, glutamate, and neuropeptides. Cold Spring Harb Perspect Med 2012;2:a012195
   PubMed Web of Science ®Google Scholar
• Cushman JD, Moore MD, Jacobs NS, Olsen RW, Fanselow MS. Behavioral pharmacogenetic analysis on the role of the α4 GABA(A) receptor subunit in the ethanol-mediated impairment of hippocampus-dependent contextual learning. Alcohol Clin Exp Res 2011;35:1948–1959
   Google Scholar
• Matthews DB, Morrow AL. Effects of acute and chronic ethanol exposure on spatial cognitive processing and hippocampal function in the rat. Hippocampus 2000;10:122–130
   PubMed Web of Science ®Google Scholar
• Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav 2007;87:65–72
   PubMed Web of Science ®Google Scholar
• Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption in C57BL/6 mice. Synapse 2007;61:150–156
   PubMed Web of Science ®Google Scholar
• Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment of ethanol consumption in rats. Psychopharmacology (Berl) 2010;207:529–534
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daous N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361:1677–1685
   PubMed Web of Science ®Google Scholar
• Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose of topiramate: an open-label controlled study. BMC Psychiatry 2011;11:41
   PubMed Web of Science ®Google Scholar
• Arias A, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 2010;30:318–322
   PubMed Web of Science ®Google Scholar
• Sarid-Segal O, Knapp CM, Burch W, Richardson MA, Bahtia S, DeQuattro K, Asfhar M, et al. The anticonvulsant zonisamide reduced ethanol self-administration by risky drinkers. Am J Drug Alcohol Abuse 2009;35:316–319
   PubMed Web of Science ®Google Scholar
• Crean CS, Tompson DJ. The effects of ethanol on pharmacokinetics, pharmakodynamics, safety and tolerability of ezogabine (retigabine). Clin Ther 2013;35:87–93
   Google Scholar
• Hiller A, Nguyen N, Strasburg CP, Li Q, Jainta H, Pechstein B, Ruus P, et al. Retigabine n-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605–612
   PubMed Web of Science ®Google Scholar
• Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B. Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther 2001;298:737–743
   PubMed Web of Science ®Google Scholar
• Manto M, Laute MA, Pandolfo M. Depression of extra-cellular GABA and increase of NMDA-induced nitric oxide following acute intra-nuclear administration of alcohol in the cerebellar nuclei of the rat. Cerebellum 2005;4:230–238
   Google Scholar
• Young C, Olney JW. Neuroapoptosis in the infant mouse brain triggered by a transient small increase in blood alcohol concentration. Neurobiol Dis 2006;22:548–554
   PubMed Web of Science ®Google Scholar